207 related articles for article (PubMed ID: 31037562)
21. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
22. [Clinical study of radical prostatectomy for prostate cancer from a single institution].
Ishida R; Kobayashi H; Yoshida S; Ogawa M; Shiota T; Nishikimi T; Yamada H; Yokoi K
Nihon Hinyokika Gakkai Zasshi; 2009 Sep; 100(6):615-24. PubMed ID: 19827538
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
24. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D
BJU Int; 2004 Feb; 93(3):275-8. PubMed ID: 14764122
[TBL] [Abstract][Full Text] [Related]
26. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy.
Chuang AY; Nielsen ME; Hernandez DJ; Walsh PC; Epstein JI
J Urol; 2007 Oct; 178(4 Pt 1):1306-10. PubMed ID: 17698141
[TBL] [Abstract][Full Text] [Related]
27. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
29. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
30. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
Koontz BF; Quaranta BP; Pura JA; Lee WR; Vujaskovic Z; Gerber L; Haake M; Anscher MS; Robertson CN; Polascik TJ; Moul JW
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):88-93. PubMed ID: 23790772
[TBL] [Abstract][Full Text] [Related]
33. Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy.
Sato N; Shiota M; Shiga KI; Kashiwagi E; Takeuchi A; Inokuchi J; Yokomizo A; Naito S; Eto M
Cancer Invest; 2020 Nov; 38(10):559-564. PubMed ID: 33016145
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
[TBL] [Abstract][Full Text] [Related]
35. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
36. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Armstrong AJ; Halabi S; Healy P; Lee WR; Koontz BF; Moul JW; Mundy K; Creel P; Wood S; Davis K; Carducci MA; Stein M; Hobbs C; Reimer B; Nguyen M; Anand M; Bratt L; Kim S; Tran PT; George DJ;
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):100-6. PubMed ID: 26754260
[TBL] [Abstract][Full Text] [Related]
38. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
[TBL] [Abstract][Full Text] [Related]
39. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant hormonal therapy in carcinoma of the prostate.
Lee HH; Warde P; Jewett MA
BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
